Tech Company Financing Transactions
Arkuda Therapeutics Funding Round
Cormorant Asset Management, Atlas Venture and Eli Lilly and Company participated in a $64 million Series B venture round for Arkuda Therapeutics. This venture round was announced on 2/18/2022.
Transaction Overview
Company Name
Announced On
2/18/2022
Transaction Type
Venture Equity
Amount
$64,000,000
Round
Series B
Investors
Proceeds Purpose
Funding to support progression of lead progranulin enhancer program into IND-enabling studies
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Arsenal Yards Blvd, Suite 220, 200
Watertown, MA 02472
USA
Watertown, MA 02472
USA
Phone
Website
Email Address
Overview
Arkuda Therapeutics is a biotechnology company leveraging new insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Gerhard Koenig
Chief Financial Officer
Joanne Bryce
Vice President
Duane Burnett
VP - Bus. Development
Andrew Hu
VP - R & D
Toni Williamson
Browse more venture capital transactions:
Prev: 2/18/2022: Ventus Therapeutics venture capital transaction
Next: 2/18/2022: Destinus venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions on this site are sourced from company press releases and news coverage. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs